Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson’s disease
Open Access
- 1 December 2012
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (23), 7183-7188
- https://doi.org/10.1016/j.bmcl.2012.09.056
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptorsExpert Opinion on Investigational Drugs, 2012
- Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological TherapiesCurrent Topics in Medicinal Chemistry, 2011
- The relevance of iron in the pathogenesis of Parkinson’s diseaseJournal of Neurochemistry, 2010
- Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidaseArchives of Pharmacal Research, 2008
- Black Pepper and its Pungent Principle-Piperine: A Review of Diverse Physiological EffectsCritical Reviews in Food Science and Nutrition, 2007
- The therapeutic potential of monoamine oxidase inhibitorsNature Reviews Neuroscience, 2006
- Piperine from the Fruits of Piper longum with Inhibitory Effect on Monoamine Oxidase and Antidepressant-Like ActivityCHEMICAL & PHARMACEUTICAL BULLETIN, 2005
- Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinonesJournal of Ethnopharmacology, 2004
- Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4The Journal of pharmacology and experimental therapeutics, 2002
- Striatal Dopaminergic Pathways as a Target for the Insecticides Permethrin and ChlorpyrifosNeuroToxicology, 2001